Recent Updates
Recently added Catalysts
AGMB Positive Sentiment

Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial

Thursday, October 5, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agomab Therapeutics has announced that it has received Fast Track Designation from the FDA for its drug AGMB-129, aimed at treating Fibrostenosing Crohn's Disease. Additionally, the company has commenced the STENOVA Phase 2a clinical trial to evaluate the efficacy of AGMB-129. This designation may expedite the development process for the treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agomab received Fast Track Designation from the FDA.
  • AGMB-129 is being developed for Fibrostenosing Crohn’s Disease.
  • The initiation of the STENOVA Phase 2a clinical trial is a significant step.

Full Press Release Details

– Agomab Therapeutics NV (‘Agomab’) today announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). In addition, Agomab has initiated its STENOVA Phase 2a clinical trial evaluating AGMB-129.

Frequently Asked Questions

What is AGMB-129 used for?

AGMB-129 is being developed for the treatment of Fibrostenosing Crohn’s Disease.

What designation did AGMB-129 receive from the FDA?

AGMB-129 received Fast Track Designation from the FDA.

What is the STENOVA trial?

The STENOVA trial is a Phase 2a clinical trial evaluating AGMB-129.

Who is developing AGMB-129?

AGMB-129 is being developed by Agomab Therapeutics NV.

ShareAdd on Google
Tags: AGMB Viatris Investor Conferences Healthcare Agomab AGMB-129 Fibrostenosing Crohn’s Disease FDA Fast Track Phase 2a trial
Last updated: Oct 5, 2023

Biotech snapshot

Lead asset
AGMB-129Phase 2
Fibrostenotic Crohn's Disease →